#China #Shanghai #Fangzhou Inc #Bristol Myers Squibb #Internet Healthcare

Fangzhou Inc. and Bristol Myers Squibb Team Up for Internet Healthcare Innovation

On December 16, 2024, Fangzhou Inc., one of China’s leading companies in Internet healthcare solutions, announced a strategic partnership with Bristol Myers Squibb (BMS) China. This collaboration was formally marked by a signing event that featured key figures from both companies, including Dr. Xie Fangmin, the founder and CEO of Fangzhou, and Mr. Wen Yizhong, the head of BMS's Innovative Medicines Division in China.

Aims and Objectives of the Alliance

The main goal of this strategic alliance is to leverage the strengths of each company to foster innovative solutions in Internet healthcare. The collaboration is set to focus on developing state-of-the-art digital platforms for managing chronic diseases over the Internet. This initiative is expected to enhance the delivery and accessibility of healthcare for millions of patients across China.

By combining Fangzhou’s exceptional technological capabilities with BMS's extensive research and development expertise, both organizations aim to progress the digital healthcare landscape. Notably, this partnership will also center on two of BMS's latest products available in China:

• - Reblozyl® (利布洛泽®) for managing β-thalassemia.
• - Sotyktu® (颂狄多®), a selective TYK2 inhibitor for plaque psoriasis treatment.

According to Dr. Xie, the merger of Fangzhou's technological prowess and BMS’s research capabilities represents a promising opportunity to push digital healthcare forward. Similarly, Mr. Wen underscored the history of productive cooperation between BMS and Fangzhou, expressing confidence in the partnership's potential to achieve a combined impact greater than their individual efforts.

The Future of Internet Healthcare in China

Looking ahead, Fangzhou and BMS intend to harness their collective strengths to establish a robust platform for chronic disease management. Their ambitions include creating seamless omnichannel collaborations that enhance the efficacy of healthcare services delivered through the Internet.

This partnership not only signals a significant advancement in the approach to chronic disease care but also highlights a pivotal moment for healthcare technology in China. The two companies are committed to creating sustainable healthcare innovations that will benefit patients long into the future.

About Fangzhou Inc.

Fangzhou Inc. stands out as one of the most prominent online platforms for chronic disease management in China. As of June 30, 2024, the company boasts an impressive user base of 45.6 million registered users and over 217,000 registered doctors, positioning it as a leader in delivering tailored healthcare solutions.

About Bristol Myers Squibb

Bristol Myers Squibb is a renowned global biopharmaceutical entity actively engaged in discovering and developing cutting-edge medicines in various therapeutic areas, including oncology, immunology, and cardiovascular diseases. Their mission is focused on making innovative therapies accessible to patients in need.

This alliance between Fangzhou and BMS represents a significant stride toward revolutionizing healthcare delivery in the digital age, setting new benchmarks for excellence in patient care and medical technology in China.